Azenta, Inc. · NASDAQ:AZTA
Azenta — Investor Day (December 2025)
62 slides from Azenta's investor day presentation, Dec 10, 2025
Slide 1: Investor Day 2025
Lycee INVESTOR»), 9 DAY 2025''
Slide 2: Welcome & Opening Remarks
Welcome & Opening Remarks Yvonne Perron VP, Head of FP&A and Investor Relations
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21 of the Securities Exchange Act of 1934, each as amended. Forward looking statements may be
Slide 4: Today's Agenda
Today’s Agenda 1:00 PM Welcome and Opening Remarks Yvonne Perron | VP, Head of FP&/ and Investor Relations ‘Company Overview and Strat John Marotta | President and Chief Executive Officer ‘Sample Management Solutions ‘Alex Esmon | VP and GM of Sample Repository Solutions (SRS) Multiomics (GENEWIZ) G
Slide 5: Company Overview and Strategy
Company Overview and Strategy John Marotta h President and CEO
Slide 6: Key Messages
Key Messages @) @) ®) ®) ©) Uniquely positioned with a strong top-line growth trajectory, meaningful margin expansion potential, and clear opportunities for inorganic growth Category leader with best-in-class solutions in attractive, niche categories tied to strong secular growth markets Deep instal
Slide 7: Large and Growing Addressable Market
Large and Growing Addressable Market Current SAM*: ‘ CURRENT EXPECTED ~$6B as — Multiomics ~$3B Significant Opportunity to Captui in a Large and Growing Market
Slide 8: Well-Positioned to Capitalize on Secular Growth Trends
Well-Positioned to Capitalize on Secular Growth Trends FDA aj requirements are Becoming e stringent Life science spend Productivity is becoming is substantial. bh Outsourcing trend... Mier Secerio Pinte ati nen Sie ee SETS Nae Rae ee lant ny oO o {y) (v) {Vv} ) ~$350B >50% 248 ~50% nee amen an nears
Slide 9: Azenta Today
Azenta Today aS $594M revenue +3% organic Yor ~55% recurring Revenue! 44,000 60M Samples Ox. Mace @) imsemoees, B) Ssmoes ED) sereny sore " ei supported Revenue by Segment. Revenue by End Market Geographic Mix 45% 46% 24% Mutiomics Medical/ (GENEWZ) Gov. Non rot other 55% 54% Semple Pharmay Manageme
Slide 10: Initial Impressions Since Joining as CEO
Initial Impressions Since Joining as CEO STRONG FOUNDATION *» PIVOTING TO GROWTH & PERFORMANCE + Highly Portfolio of solutions creating an ecosystem * Deep focus on the + Redirecti idly to high heavy GA; customer with a passion investing in high margin, high ROIC parts ofthe business toserve : ly we
Slide 11: Comprehensive Suite of Solutions to Enable Breakthroughs Faster
Comprehensive Suite of Solutions to Enable Breakthroughs Faster Guardians of the Most Critical Assets for y + Pre Clinical Studies to Clini Sample Solutions (SMS) (GENEWIZ) 2 iW e Biorepositories Gene Sequencing? ‘Sotudons! Synthesis LIMS? for Biological Asset Management LIMS$ for Multiomics Data Ma
Slide 12: The Only Player with Full Capabilities to Address Customers' Needs
The Only Player with Full Capabilities to Address Customers’ Needs Automated storage & integrated solutions © Reading and wrting 6: ies enabling pci inoreased research productivity (3-10x increased research output) @ Software solutions fii) OFF site biorepositories (e.g., LIMS? system) rdians of the
Slide 13: Key Enabler of the Life Sciences Ecosystem
Key Enabler of the Life Sciences Ecosystem Customer Samples Customer Samples Partner with our customer to ensure integrity of samples during planning, Storage customer location and can quickly retrieve Testing 1 Customers and/or Azenta test sar assemble, and evaluate data to determine the next steps
Slide 14: Customers Searching for the Right Partner to Eliminate Pain Points
Customers Searching for the Right Partner to Eliminate Pain Points ——<— — GG Fundamentally, automation GG Azenta has been a strong GG Azenta is an outstanding enables scale...Azenta is a partner to GSK over many partner in our transformation journey... years. The interactions to understand and desig
Slide 15: Executing Strategy to Drive Long-Term Value Creation
Executing Strategy to Drive Long-Term Value Creation for Shareholders @ © @ DRIVE > REINVEST ————~ DEPLOY = Operational In Profitable Capital Prudently Excellence , and Strategically * Scale Biorepositories nalize Synthesis * Technology and Automated Solutions
Slide 16: Drive Operational Excellence
Drive Operational Excellence ® Early Innings of Our Operational Excellence Journey IMPLEMENTING AND EXECUTING ABS Manufacturing & Back Office Efficiency + Driving safety, quality, and on-time delivery (OTD) * Optimizing working capital management + Delivering enhanced productivity and efficiency thr
Slide 17: Drive Operational Excellence: Early Successes
Drive Operational Excellence Early Successes in Operations & Manufacturing FOCUS AREA WHAT WE HAVE DONE FUTURE PRIORITIES Improve Quality Preemie reduced Target <2% Enhance Delivery V CBI OTD improved by 30% + >95% OTD Reduce Costs Y GBA reduced by 3% . ie ead a Working Capital P . Managsneel DSO do
Slide 18: Reinvest in Profitable Growth
Reinvest in Profitable Growth Delivering Growth across Three Core Vectors ocreseeeeed Scale Biorepositories Capitalize on coming wave of sample growth D veered Regionalize Gene Synthesis Expand US. based production to accelerate delivery & meet local demand B vevseeeeey Continue to specialize in tec
Slide 19: Reinvigorating Our Go-to-Market Approach
Reinvest in Profitable Growth © Reinvigorating Our Go-to-Market Approach KEY FOCUS AREAS HOW WE ARE EXECUTING + Installed localized sales & commercial team del : relationships g + Adjusted incentive plans to drive behavior Z Direct selling & + Added 25 highly skilled sales associates, Us, * Created
Slide 20: Deploy Capital Prudently and Strategically
Deploy Capital Prudently and Strategically Pursuing Targeted Actions to Drive Value Accretion OUR PRIORITIES 5 Productivity & GM Improvement Share Repurchase Organic Growth ‘Strengthen accountability Double down on growth Implement disciplined Renewed commitment. ‘through systematic and investments
Slide 21: Strategic Approach to M&A
Deploy Capital Prudently and Strategically Strategic Approach to M&A Additive to Product line Current Portfolio Adjacencies Wallet Share Geographic Expansion Expansion Strengthen Recurring Capabilities, Revenue Strategic Filters Commitment to disciplined M&A Y Strategic capital deployment Economic,
Slide 22: Leadership Team Excited and Poised for the Future
Leadership Team Excited and Poised for the Future John Marotta Lawrence Lin Ginger Zhou, Ph Olga Pirogova Ephraim Starr President & EVP & Chief SVP, Presicent ‘SVP. Chief Human SVP, Gener Chief Executive Financial e Resources orticer Counsel officer officer Joined: 2011 Joined: 2023 & Corporate Join
Slide 23: Dedicated and Experienced Board
Dedicated and Experienced Board Creates Deeper Differentiation Frank Casal Watiam Cornog Marin Madus [Ee (cai of Azenta Board Former head of KKR ‘Senior Operating 3 Becuthe Experi Former Viee Chao! capstone Executve at Care po Sen cara ees ‘Aude at KPMG Group + Public Company Board Roby + Accounting
Slide 24: Investment Thesis and Value Creation
Investment Thesis and Value Creation Industry leader, Deep installed Above market Clear path to margin _Financial strength with unmatched base, providing growth potential, expansion through and strong balance ecosystem of meaningful up-sell / supported by G&Aefficiencies _sheet fuels strategic, diff
Slide 25: Sample Management Solutions (SMS)
Sample Management Solutions (SMS) Alex Esmon VP and GM, Sample Repository Solutions (SRS)
Slide 26: Sample Management Solutions Key Messages
Sample Management Solutions Key Messages @) Leading the industry with expertise and a differentiated, end-to-end solution set to manage and protect our customers’ irreplaceable assets @) Embedding the Azenta Business System into our way of working, enabling us to execute with leading quality, effici
Slide 27: Business Overview: Sample Management Solutions Today
Business Overview: Sample Management Solutions Today Our Vision $325M ~50% 4 25% CAGR FY 25 Revenue Recuring Revenue Gout of Sampies n To become the end-to-end biological some y and therapeutic asset manager of Be. ow me choice from early research to secure, wi Ne long-term storage — sone OF sevenve
Slide 28: Well-Positioned to Capture Key Market Growth Drivers & Tailwinds
Well-Positioned to Capture Key Market Growth Drivers & Tailwinds ~$38 Serviceable Addressable Market* Increase in Pre-Clinical R&D Activity + Top pharma companies increasing R&D spend ~7% since 2020 * Increasing public and private annual investment - ~$2508 public global Pharma/Biotech investment? -
Slide 29: Sustainable Competitive Advantages
Sustainable Competitive Advantages END-TO-END Unique combination of sample storage SOLUTIONS products, services, consumables, and OFFERING _ software to fully support customer needs Differentiated ‘Automation Data Reputation Expertise Capabilities Management Proven track record; Seasonediife science
Slide 30: Drive Operational Excellence
Drive Operational Excellence KEY INITIATIVES. EXPECTED OUTCOMES Drive Process Improvement through ABS Integration Drive on time delivery + Complete implementation of Lean management systems to improvement scale more efficiently * Conduct ongoing Kaizens to drive continuous improvement NE : from top
Slide 31: Biorepositories: Reinvest in Profitable Growth
Biorepositories: Reinvest in Profitable Growth Grow Customer Off-site Sample Storage Solutions Deepen penetration by increasing the number and types of samples stored Capitalize on scalability to deliver growth with strong profitability Geographical expansion in core markets Scale Customer On-site O
Slide 32: Automated Solutions: Reinvest in Profitable Growth
Automated Solutions: Reinvest in Profitable Growth Elevate Digital Experience Provide unified experience supported by harmonized software Develop and release eCommerce platform } Evolve leadership in Automation Modularizing Vaults - make it easier for customers to “click and build” automated storage
Slide 33: Case Study: Unique Customer Solution
Case Study: Unique Customer Solution . . ™ Customer Need Our Unique Solution ® Results Key customer in arma produto, Created an integrated process connecting 45 to market with an tasked with . . integrated solution for faster non-clinical tral data data reporting in a new facility thet included tria
Slide 34: Sample Management Solutions Key Takeaways
Sample Management Solutions Key Takeaways ©) Leading the industry with expertise and a differentiated, end-to-end solution set to manage and protect our customers’ irreplaceable assets ) Embedding the Azenta Business System into our way of working, enabling us to execute with leading quality, effici
Slide 35: Multiomics
Multiomics Ginger Zhou y Fe a 8 5 3 £ g a (\AZENTA
Slide 36: Multiomics (GENEWIZ) Key Messages
Multiomics (GENEWIZ) Key Messages Uniquely positioned with 26 years of sequencing & synthesis expertise @) combined with unparalleled speed, convenience, and portfolio breadth making us a one-stop-shop 2) Driving operational excellence leveraging the Azenta Business System for customer satisfaction
Slide 37: Years of Reading and Writing Genes
26 Years of Reading and Writing Genes To accelerate scientific discovery by providing researchers high-quality, reliable, innovative multiomics solutions il Illi. Sequencing Sotutions Gene Synthesis Solutions Highest throughput Sequencing Amanufactured gene of cores comple tues soutstandard ny seque
Slide 38: Business Overview: Multiomics (GENEWIZ) Today
Business Overview: Multiomics (GENEWIZ) Today $269M >70% TRUSTED PARTNER OF: See 8,000+ rote Retort @ 22" @)ipsusions >37 Nobel Laureate Labs 5% Mexcover 21% \ 1 Sine “" 7%, gee Secon Revenue by mess Regon — End Markets \ 57% 63% a ny 17% ope
Slide 39: Sustainable Competitive Advantages
Sustainable Competitive Advantages Trusted Brand with Deep Domain Speed & 26 years of know how, emphasizing solid science & superior service GG Your lab set a new bar for AAV.ITR sequencing across the industry and has helped many researchers including mysetf. Senior Principal Scientist, F Novartis I
Slide 40: Well-Positioned to Capture Key Market Growth Drivers & Tailwinds
Well-Positioned to Capture Key Market Growth Drivers & Tailwinds ~$3B Serviceable Addressable Market MARKET TAILWINDS. ~$1.5B ‘Sequencing Opportunity + Growth in outsourcing as Pharma & Biotechs optimize for efficiency + Researchers have greater access to technologies at a lower cost 5B > * Increase
Slide 41: Executing Strategic Initiatives to Drive Shareholder Value
Executing Strategic Initiatives to Drive Shareholder Value DRIVE Operational Excellence @ © REINVEST in Profitable Growth ABS Toolbox Implementation * Further improve deliverable speed and quality © Continue to drive efficiencies that enhance customer experience and improve productivity, /\ AZENTA ‘
Slide 42: Case Study: Supporting Clinical Trials
Case Study: Supporting Clinical Trials Targeting Breakthrough Solution for Rare Childhood Disease Customer Need Our Unique Solution Customer planning Phase 1 trial GENEWIZ proposed a unique solution to treat rare childhood disease leveraging longread sequencing resulting in blindness technology to o
Slide 43: Multiomics (GENEWIZ) Key Takeaways
Multiomics (GENEWIZ) Key Takeaways Uniquely positioned with 26 years of sequencing & synthesis expertise combined with unparalleled speed, convenience, and portfolio breadth making us a one-stop-shop i) Driving operational excellence leveraging the Azenta Business System (ABS) for customer satisfact
Slide 44: Financial Overview
Financial Overview \ Lawrence Lin | ag | Executive Vice President and CFO /\AzENTA
Slide 45: Key Messages
Key Messages (4) Building on a strong financial foundation with key initiatives in place to drive revenue growth (2) Capturing meaningful margin expansion opportunities through gross margin expansion and G&A efficiencies (3) Driving increased expense discipline and cost optimization to increase rein
Slide 46: Initial Impressions since Joining as CFO
Initial Impressions since Joining as CFO STRONG FOUNDATION PIVOTING TO GROWTH WITH CLEARLY IDENTIFIED IMPROVEMENT AREAS. * Portfolio and product. process * Talent and desire of team members to * Creating product line P&L and financial rigor win and continuously get better + Strength of balance sheet
Slide 47: Driving Growth through Strategic Investments
Driving Growth through Strategic Investments Key Areas for Strategic Organic Growth Investments @ Scale Biorepositories * Continuing to expand SRS facilities and increase automation * Grow off-site and on-site storage solutions (2) Regionalize Gene Synthesis * Expand U.S. based production to acceler
Slide 48: Driving Margin Improvement through Strategic Investments
Driving Margin Improvement through Strategic Investments Margin Expansion Initiatives © Optimizing G&A for greater operational leverage + Improving processes while aligning the right resources to the right work © Pursuing price optimization + Implementing strategies for pricing optimization adoption
Slide 49: Balanced and Disciplined Capital Allocation Strategy
Balanced and Disciplined Capital Allocation Strategy ‘Ample Liquidity and Improving Free Cash Flow Long-term Capital Allocation Priorities Generation to Fund Capital Deployment Prodetity & Gross Mersin norvement + hecleatedodopion of AS across the organization Cash Improving or 1 ganic Growth OME So
Slide 50: Strategic Approach to M&A
Strategic Approach to M&A Evaluate through Strategic Lens Greater Commitment to Disciplined M&A (OTN Preduck Ine with Financial Guiding Principles Current Portfolio Adjacencies ¥ Strong Organic Growth Potential Expansion: ‘Strengthen, Capabilities nd Financial tify Strongly Aligned Tuck-in Opportuni
Slide 51: Reiterating 2026 Guidance
Reiterating 2026 Guidance FY'2026 Organic Growth: 3% to 5% YoY Revenue Sample Management Solutions: MSD Multiomics: LSD. IXWSe) S55) ) 8 300 bps of Adjusted EBITDA margin expansion Interest Income: $16M - $18M Tax Rate: 27% - 29% Other Continuing to Track Toward Our Previously Announced Targets fete
Slide 52: Introducing 2028 Organic Financial Targets
Introducing 2028 Organic Financial Targets $700 - $750M Revenue 6% - 8% CAGR* $120 - $1450M $200 - $250M Adj. EBITDA Cumlewe 18-20% 3Ye Adj. EBITDA Margin? Recurring Revenue Free Cash Flow! |-Positioned to Drive Performance Im| 13 20252028 CR 2 Trees rcv a pcg ote event een ot FY2028, adn cet bess o
Slide 53: Revenue Bridge
Revenue Bridge ~20% — $700M-$750M —_ + Direct Seling alization + Product Marketing Fv25 Market& Growth nittves Pree (nom Commerc! Fy28 Investment Revenve Target Key Assumptions * LSD market growth » Strategic initiatives and NPI contribute >50% * Commercial investment of feet on the street and downs
Slide 54: Adjusted EBITDA Margin Bridge
Adjusted EBITDA Margin Bridge . iz 11% 4700-900 bps ‘expansion Fr25A. Volume & Mx Productity Procurement, rr 28 Aa EBITDA Margin ‘GaASovings EBITDA Margin Target rational Effi Position Us Key Annual Assumptions: * Gross margin expands >200bps * G&A and Indirect savings yield 100bps * Adj. EBITDA exp
Slide 55: Key Takeaways
Key Takeaways ©) Building on a strong financial foundation with key initiatives in place to drive revenue growth and margin improvement @) Capturing ingful margin i ities through gross margin expansion and G&A efficiencies (©) Increasing reinvestment in the business to drive future revenue growth ®
Slide 56: Closing Remarks
Closing Remarks : » John Marotta a je h President and CEO
Slide 57: Investment Thesis and Value Creation
Investment Thesis and Value Creation Industry leader, with unmatched ecosystem of differentiated customer solutions Above market growth potential, supported by dlscplined investments in R&D, sales & Clear path to mark implementation of ABS
Slide 58: Azenta Life Sciences
AZENTA LIFE SCIENCES [BRENT
Slide 59: Q&A
Q&A
Slide 60: Azenta Life Sciences
AZENTA LIFE SCIENCES.
Slide 61: Solid Financial Position
Solid Financial Position Adjusted EBITDA ($M) and Margin (%)* Revenue ($M)? {Lacs noe B Maal ers LA BRENTA sonranstree ot
Slide 62: Net Income to Adjusted EBITDA Reconciliation
Net Income to Adjusted EBITDA Reconciliation Continuing Operations ‘Sion except percemages ra pres 128 Netincome az) ots) 87) (isco) Lass am ascennued operations. nto a 66 4403 222 Net income (oss rm contigapeations ey iaaay 245 rer 35) 29) ass) Income tox rovson dis) 32 (316) Depreation 209 27 "320